Sponsor pipeline

ORIC Pharmaceuticals clinical trial pipeline

Get alerts when ORIC Pharmaceuticals's trials change

4 active trials 4 recruiting 1 Phase 3 2 disease areas 1 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-11

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1
2
Phase 1/2
1
Phase 3
1

Active trials

NCT IDTitleConditionStatusUpdated
Phase 3
NCT07723248 A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With… Metastatic Castration Resistant Prostate Cancer Recruiting 2026-10-05
Phase 1/2
NCT05315700 Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2… Solid Tumors Recruiting 2026-09-04
Phase 1
NCT05413421 Study of ORIC-944 in Patients With Metastatic Prostate Cancer Metastatic Prostate Cancer Recruiting 2026-07-09
NCT06816992 ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20… Solid Tumors Recruiting 2026-04-24

Disease areas by active trials

Prostate Cancer (2) · Non-Small Cell Lung Cancer (NSCLC) (1)

Get alerts when ORIC Pharmaceuticals's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free